We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. Read more about our Privacy Policy.

I got it!

Event
23 Mar 2017
Biotechnology

Annual Bispecific Antibody Lisbon Summit

The Curtis & Wyss Group is pleased to invite you to the, Annual Bispecific antibody Lisbon summit, scheduled on March 23-24, 2017 in Lisbon, Portugal.

This premier B2B event will focussed completely on the development of bispecifics Antibody, the Annual Bispecific antibody Lisbon summit represents a unique opportunity to engage with your peers to discuss strategies to overcome the key challenges holding back progress in the field. 

Built using insights from experts, this year’s Bispecific Antibody Lisbon summit will incorporate more developmental and clinical insights than ever before. Rather than presenting vague overviews of platforms, this meeting will delve directly into the technical and scientific insights that will enable you to advance your candidate therapeutic into the clinic as efficiently and cost-effectively as possible. 

 

Key Practical Learning Points of the Summit: 

  • Optimize early decision makingto guarantee target synergy early in the development of multispecific therapeutics, with insights into Sanofi’s novel bispecific development programs
  • Validate bispecific formats in comparison with monoclonal approachesby learning from innovative analytical approaches, including Janssen’s dual binding and single target assays
  • Understand how Pfizer have enhanced bispecific IgG generation by bypassing the need for post purification recombination processes
  • Improve translatability into the clinic by investigating how Immunocore maximize the predictability of in vitro models
  • Investigate novel multispecific approaches for applications spanning beyond oncology, including in- depth case studies into innovative bispecific programs in autoimmune, neurodegenerative and infectious disease indications
  • Determine the characteristics required to ensure clinical success by examining key factors from clinical bispecific programs at Merrimack, Amgen and Macrogenics
  • Leave World Bispecific with clear insights that will dramatically improve the success of your bispecific development

 

WHY should you be there?

CEO, CSO, VP, Director, Head and Scientists in: 

  • Bispecifics
  • Antibody/Biologics
  • R&D
  • Therapeutic Areas
  • Discovery
  • Target ID & Validation
  • Process Development
  • Manufacturing/CMC
  • Bioanalysis
  • PKPD/ADME/Tox
  • Clinical Development
  • Business Development

When

23 Mar 2017 @ 08:30 am

24 Mar 2017 @ 05:00 pm

Duration: 1 days, 8 hours


Where

Lisbon

Lisbon

13000 Lisbon

Portugal


Language

English en


Organised by

Curtis Wyss (deactivated)

Other Events in Science

SLS&OPTIROB 2024

Romania, 27 Jun 2024

Similar Webinars in Science

Recent Publications in Science

PASSENGER: a solution for futureproof permanent magnets made in Europe

Fact-sheet, Apr 2024, ESF - PASSENGER project